Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $11.46, for a total value of $85,950.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,161,054.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Amicus Therapeutics Trading Up 3.6 %

Shares of Amicus Therapeutics stock opened at $11.74 on Wednesday. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The business’s 50 day moving average is $11.14 and its 200-day moving average is $10.59. The stock has a market cap of $3.48 billion, a P/E ratio of -30.10 and a beta of 0.68.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.15) earnings per share. Equities research analysts predict that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on FOLD. Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 31st. Jefferies Financial Group began coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research report on Friday, September 20th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.13.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Xponance Inc. raised its stake in Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 936 shares during the period. Hazlett Burt & Watson Inc. raised its position in shares of Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Arizona State Retirement System lifted its stake in shares of Amicus Therapeutics by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 1,577 shares during the last quarter. American International Group Inc. boosted its holdings in shares of Amicus Therapeutics by 1.3% during the 1st quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after buying an additional 1,785 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,884 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.